{"id":23822,"date":"2024-01-23T12:38:27","date_gmt":"2024-01-23T20:38:27","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/understanding-the-potential-risks-of-ivig-therapy-2\/"},"modified":"2025-06-04T15:48:03","modified_gmt":"2025-06-04T22:48:03","slug":"understanding-the-potential-risks-of-ivig-therapy-2","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/","title":{"rendered":"Comprender los riesgos potenciales de la terapia con IgIV"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">A pesar de <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/ivig\/\">inmunoglobulina intravenosa (IVIG)<\/a> La terapia se considera una intervenci\u00f3n m\u00e9dica eficaz y segura para el tratamiento de diversos trastornos inmunomediados. Sin embargo, tambi\u00e9n conlleva riesgos. Estos riesgos pueden ser leves y transitorios, como s\u00edntomas gripales, o causar problemas de salud graves, como un accidente cerebrovascular o reacciones al\u00e9rgicas graves.\u00a0<\/span><\/p>\n\n\n<div  id=\"call-to-action-17059ce615c3f540b4c9c86a10d4d4b9\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tAsistencia para el copago de IgIV | Asistencia financiera para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<p><span style=\"font-weight: 400;\">Si estas recibiendo <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/what-to-expect-during-your-ivig-infusion-treatment\/\">Tratamiento con IgIV<\/a> A largo plazo, debes ser consciente de estos riesgos para evitar complicaciones.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">En este art\u00edculo, describiremos brevemente los posibles riesgos asociados con la terapia con IgIV y ofreceremos algunas medidas preventivas que pueden ayudar a reducir o controlar activamente los riesgos de la terapia con IgIV.<\/span>\u00a0<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Basics_of_IVIG\" >Conceptos b\u00e1sicos de la IgIV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#What_Are_the_Risks_of_IVIG_Therapy\" >\u00bfCu\u00e1les son los riesgos de la terapia con IgIV?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Allergic_Reactions\" >Reacciones al\u00e9rgicas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Renal_Kidney_Impairment\" >Insuficiencia renal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Thrombotic_Events\" >Eventos tromb\u00f3ticos<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Hemolysis_and_Neutropenia_Hematologic_Disorders\" >Hem\u00f3lisis y neutropenia (trastornos hematol\u00f3gicos)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Aseptic_Meningitis\" >Meningitis as\u00e9ptica<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#Infection_Risk\" >Riesgo de infecci\u00f3n<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#How_Can_You_Reduce_the_Risks_of_IVIG\" >\u00bfC\u00f3mo se pueden reducir los riesgos de la IgIV?<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Basics_of_IVIG\"><\/span>Conceptos b\u00e1sicos de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">La terapia con IgIV se utiliza principalmente para tratar la deficiencia de anticuerpos en personas que carecen de anticuerpos esenciales (tambi\u00e9n conocidos como <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/immunoglobulins-ig\/\">inmunoglobulinas<\/a>) debido a una afecci\u00f3n m\u00e9dica, como un trastorno de inmunodeficiencia primaria. Las inmunoglobulinas que se proporcionan mediante esta terapia se elaboran a partir de miles de donaciones de plasma sangu\u00edneo sano y ayudan al sistema inmunitario a combatir infecciones.<\/span><br \/><span style=\"font-weight: 400;\">La IgIV tambi\u00e9n puede utilizarse como tratamiento antiinflamatorio. Puede ser \u00fatil para reducir la inflamaci\u00f3n causada por la hiperactividad del sistema inmunitario en trastornos autoinmunes.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">En general, la terapia con IgIV tiene diversos modos de acci\u00f3n, lo que hace de esta terapia un tratamiento est\u00e1ndar para diversos trastornos relacionados con el sistema inmunitario.\u00a0<\/span>\u00a0<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_the_Risks_of_IVIG_Therapy\"><\/span>\u00bfCu\u00e1les son los riesgos de la terapia con IgIV?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Al igual que otros tratamientos m\u00e9dicos, la IgIV presenta ciertos riesgos que pueden causar graves problemas de salud si no se trata a tiempo. Varios estudios cl\u00ednicos han reportado la incidencia de eventos adversos asociados con la administraci\u00f3n de IgIV. Algunos de los eventos reportados son los siguientes:\u00a0<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Allergic_Reactions\"><\/span>Reacciones al\u00e9rgicas<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">El riesgo de desarrollar reacciones al\u00e9rgicas es com\u00fan en pacientes que reciben infusiones de IgIV. Estas reacciones pueden estar asociadas con los componentes de la IgIV utilizados durante las infusiones. Las reacciones leves pueden manifestarse como cefaleas, s\u00edntomas gripales, urticaria (ronchas), fiebre, escalofr\u00edos, opresi\u00f3n en el pecho, dolor de espalda, n\u00e1useas, angioedema (hinchaz\u00f3n de labios\/cara) y diarrea.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">Las personas tambi\u00e9n pueden experimentar reacciones al\u00e9rgicas graves como la anafilaxia, que es poco frecuente, pero puede ocurrir. Por ejemplo, en un informe de caso, una mujer de 57 a\u00f1os con s\u00edndrome de Crow-Fukase experiment\u00f3 <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14503355\/\"><span style=\"font-weight: 400;\">Shock anafil\u00e1ctico inmediatamente despu\u00e9s del inicio de una segunda dosis alta de IgIV<\/span><\/a><span style=\"font-weight: 400;\">Esto se debe a la hipersensibilidad del paciente a un producto de IgIV (p. ej., gammaglobulina tratada con polietilenglicol). La anafilaxia suele caracterizarse por una inflamaci\u00f3n grave, a menudo en cuesti\u00f3n de minutos, de la cara, los labios, la lengua o la garganta, con dificultad para respirar o disnea. Adem\u00e1s, algunos pacientes pueden experimentar dolor abdominal, diarrea o v\u00f3mitos, adem\u00e1s de taquicardia o mareos.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Renal_Kidney_Impairment\"><\/span>Insuficiencia renal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">La insuficiencia renal es otro riesgo asociado con la administraci\u00f3n de IgIV. Es un problema poco frecuente, pero grave y potencialmente mortal. En particular, las personas mayores con problemas renales preexistentes, diabetes persistente y deshidrataci\u00f3n tienen un mayor riesgo de insuficiencia renal tras el tratamiento con IgIV. La IgIV puede afectar la funci\u00f3n renal, lo que puede provocar disfunci\u00f3n o da\u00f1o renal en algunas personas.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">Tras el inicio de la infusi\u00f3n de inmunoglobulina, la insuficiencia renal suele aparecer en un plazo de 10 d\u00edas. Investigaciones previas han indicado que <\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0049017204001362\"><span style=\"font-weight: 400;\">8\u201315% de estas personas mueren<\/span><\/a><span style=\"font-weight: 400;\">Sin embargo, la mayor\u00eda de estos pacientes presentan problemas m\u00e9dicos subyacentes graves, como edad avanzada, antecedentes de insuficiencia renal o diabetes no controlada. Por lo tanto, se necesita m\u00e1s investigaci\u00f3n para determinar la causa de este resultado.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Thrombotic_Events\"><\/span>Eventos tromb\u00f3ticos<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Los eventos tromb\u00f3ticos son un grupo de afecciones que se producen como resultado de una trombosis (un co\u00e1gulo sangu\u00edneo en una vena, arteria o el coraz\u00f3n). Este co\u00e1gulo puede obstruir total o parcialmente la circulaci\u00f3n sangu\u00ednea, lo que puede provocar eventos tromb\u00f3ticos como un accidente cerebrovascular, una embolia pulmonar (co\u00e1gulo sangu\u00edneo en los pulmones) o un infarto de miocardio (ataque card\u00edaco).\u00a0<\/span><br \/><span style=\"font-weight: 400;\">El riesgo de una incidencia tromb\u00f3tica aumenta durante la administraci\u00f3n de IgIV. Por ejemplo, una revisi\u00f3n reciente destac\u00f3 100 casos en los que <\/span><span style=\"font-weight: 400;\">80% de eventos tromb\u00f3ticos (como accidente cerebrovascular e infarto de miocardio) ocurrieron dentro de las 24 horas posteriores a completar la infusi\u00f3n de IgIV<\/span><span style=\"font-weight: 400;\">.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">Algunos de los factores que t\u00edpicamente contribuyen a un mayor riesgo de eventos tromb\u00f3ticos durante la infusi\u00f3n de IgIV incluyen:\u00a0<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Infusi\u00f3n de una gran dosis de IgIV (m\u00e1s de 35 g de IgIV\/d\u00eda)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vejez (m\u00e1s de 45 a\u00f1os)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Personas con trombosis previa o actual<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Enfermedades hereditarias como la PTI (p\u00farpura trombocitop\u00e9nica inmunitaria)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Historia de la enfermedad ateroscler\u00f3tica<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Viscosidad s\u00e9rica elevada<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Adem\u00e1s, varios estudios han confirmado que <\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0022510X11002978\"><span style=\"font-weight: 400;\">pacientes que reciben altas dosis de IgIV<\/span><\/a><span style=\"font-weight: 400;\"> (m\u00e1s de 35 g de IgIV\/d\u00eda), tienen <\/span><a href=\"https:\/\/journals.lww.com\/jpho-online\/abstract\/2017\/11000\/dural_venous_sinus_thrombosis_and_pulmonary.39.aspx\"><span style=\"font-weight: 400;\">PTI<\/span><\/a><span style=\"font-weight: 400;\"> o <\/span><span style=\"font-weight: 400;\">enfermedad coronaria<\/span><span style=\"font-weight: 400;\">y tienen un mayor riesgo de desarrollar eventos tromb\u00f3ticos. Asimismo, se inform\u00f3 otro caso de una mujer de 43 a\u00f1os que recibi\u00f3 inmunoglobulina intravenosa en dosis altas para la dermatomiositis. <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17646563\/#:~:text=Although%20rare%2C%20stroke%20associated%20with,to%20the%20administration%20of%20IVIG.\"><span style=\"font-weight: 400;\">accidente cerebrovascular agudo<\/span><\/a><span style=\"font-weight: 400;\"> debido a una trombosis.\u00a0<\/span><br \/><span style=\"font-weight: 400;\">En general, los eventos tromb\u00f3ticos pueden desencadenarse por diversos mecanismos subyacentes de la hematopoyesis. Sin embargo, un factor, la viscosidad plasm\u00e1tica, ha demostrado representar una amenaza potencial mayor. La viscosidad plasm\u00e1tica, la densidad de la parte l\u00edquida de la sangre, puede aumentar con los tratamientos con IgIV. Una investigaci\u00f3n cl\u00ednica confirm\u00f3 que... <\/span><a href=\"https:\/\/www.jstage.jst.go.jp\/article\/circj\/69\/8\/69_8_962\/_article\/-char\/ja\/\"><span style=\"font-weight: 400;\">El tratamiento con IgIV, especialmente la concentraci\u00f3n de IgG, aumenta la viscosidad s\u00e9rica.<\/span><\/a><span style=\"font-weight: 400;\"> a lo largo del tratamiento y potencialmente desencadena eventos tromb\u00f3ticos en los pacientes.\u00a0<\/span>\u00a0<\/p>\n\n\n<div  id=\"call-to-action-6b5fcb7360da5fe477ccb3b527a4dba7\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Consulte a un especialista en IgIV<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<p>&nbsp;<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Hemolysis_and_Neutropenia_Hematologic_Disorders\"><\/span>Hem\u00f3lisis y neutropenia (trastornos hematol\u00f3gicos)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-23825 size-full\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/neutropenia.jpg\" alt=\"Diagnosis of Neutropenia\" width=\"420\" height=\"279\" \/><br \/>\n<span style=\"font-weight: 400;\">El riesgo de <\/span><a href=\"https:\/\/figshare.utas.edu.au\/articles\/journal_contribution\/Massive_intravascular_haemolysis_after_high_dose_intravenous_immunoglobulin_therapy\/23036066\/1\"><span style=\"font-weight: 400;\">hem\u00f3lisis<\/span><\/a><span style=\"font-weight: 400;\"> La neutropenia (destrucci\u00f3n de gl\u00f3bulos rojos) y la neutropenia (bajo recuento de gl\u00f3bulos blancos) son extremadamente bajas, pero pueden presentarse en pacientes que reciben infusiones de IgIV. Por ejemplo, <\/span><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/tme.12083\"><span style=\"font-weight: 400;\">La hem\u00f3lisis inducida por IgIV es mayor en pacientes con sangre tipo A (65%) o AB (26%).<\/span><\/a><span style=\"font-weight: 400;\">Esto puede deberse a la presencia de isoaglutininas A y B (anticuerpos anti-A y anti-B) en el producto de IgIV. Adem\u00e1s, varios estudios han reportado la asociaci\u00f3n de la IgIV con la hem\u00f3lisis y han confirmado que la IgIV es un factor causal de esta afecci\u00f3n.\u00a0<\/span><br \/>\n<span style=\"font-weight: 400;\">En el caso de neutropenia, el riesgo es <\/span><span style=\"font-weight: 400;\">m\u00e1s alto<\/span><span style=\"font-weight: 400;\"> en pacientes con trastornos neurol\u00f3gicos.\u00a0<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Aseptic_Meningitis\"><\/span>Meningitis as\u00e9ptica<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/14600-meningitis\"><span style=\"font-weight: 400;\">Meningitis as\u00e9ptica<\/span><\/a><span style=\"font-weight: 400;\"> Es la inflamaci\u00f3n de las meninges, la membrana protectora del cerebro. Diversos estudios han reportado que personas con trastornos neurol\u00f3gicos como la enfermedad de Kawasaki desarrollan meningitis as\u00e9ptica asociada a la inmunoglobulina intravenosa (IVIG) dentro de las 24 horas posteriores al tratamiento. El riesgo de meningitis as\u00e9ptica es poco frecuente y se presenta principalmente en personas con trastornos neurol\u00f3gicos.\u00a0<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Infection_Risk\"><\/span>Riesgo de infecci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Los productos de IgIV se preparan bajo un estricto protocolo de control de calidad y el riesgo de contraer una infecci\u00f3n transmitida por la sangre a trav\u00e9s de las infusiones de IgIV es extremadamente bajo.\u00a0\u00a0<\/span><br \/>\n<span style=\"font-weight: 400;\">La IgIV, al ser un hemoderivado, conlleva el riesgo potencial de transmitir agentes infecciosos virales como la hepatitis B, el VIH y otros. Solo se han documentado algunos casos de transmisi\u00f3n de hepatitis C en el pasado lejano.<\/span><br \/>\n&nbsp;<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Can_You_Reduce_the_Risks_of_IVIG\"><\/span>\u00bfC\u00f3mo se pueden reducir los riesgos de la IgIV?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Las siguientes son algunas medidas preventivas que su proveedor de atenci\u00f3n m\u00e9dica seguir\u00e1 para minimizar los riesgos asociados con la administraci\u00f3n de IgIV:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Seguimiento y evaluaci\u00f3n de riesgos adecuados: <\/b><span style=\"font-weight: 400;\">Dado que la IgIV conlleva cierto riesgo de efectos adversos, que podr\u00edan ser graves e incluso mortales, se obtiene la informaci\u00f3n m\u00e9dica de cada paciente antes de programar el tratamiento con IgIV. Esta informaci\u00f3n incluye su historial m\u00e9dico, edad, grupo sangu\u00edneo, pruebas de funci\u00f3n hep\u00e1tica y renal, afecciones m\u00e9dicas preexistentes (p. ej., enfermedad coronaria, accidente cerebrovascular o hipertensi\u00f3n) y su historial de medicaci\u00f3n.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Disminuir la velocidad de infusi\u00f3n de IgIV<\/b><span style=\"font-weight: 400;\">Dado que una infusi\u00f3n r\u00e1pida y alta de IgIV puede aumentar el riesgo de eventos tromb\u00f3ticos, hem\u00f3lisis y disfunci\u00f3n renal, disminuir la velocidad de infusi\u00f3n puede reducir los riesgos de la IgIV. Se recomienda iniciar la primera infusi\u00f3n de IgIV a un ritmo lento durante los primeros 30 minutos y monitorizar estrechamente a los pacientes durante y despu\u00e9s de las infusiones.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Premedicaci\u00f3n y prehidrataci\u00f3n<\/b><span style=\"font-weight: 400;\">Los profesionales de la salud pueden administrar premedicaci\u00f3n como antihistam\u00ednicos (Benadryl), AINE (ibuprofeno\/naproxeno) o corticosteroides (prednisona, metilprednisolona) antes de la infusi\u00f3n de IgIV para reducir la gravedad y la incidencia asociadas a esta. De igual manera, la prehidrataci\u00f3n con soluci\u00f3n salina normal ayuda a reducir los riesgos inducidos por la IgIV, como... <\/span><a href=\"https:\/\/journals.sagepub.com\/doi\/abs\/10.1177\/1060028015576362\"><span style=\"font-weight: 400;\">dolores de cabeza<\/span><\/a><span style=\"font-weight: 400;\">, <\/span><a href=\"https:\/\/academic.oup.com\/ced\/article-abstract\/34\/2\/145\/6624685\"><span style=\"font-weight: 400;\">tromb\u00f3lisis<\/span><\/a><span style=\"font-weight: 400;\">, <\/span><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jca.21416\"><span style=\"font-weight: 400;\">insuficiencia renal<\/span><\/a><span style=\"font-weight: 400;\">, y <\/span><span style=\"font-weight: 400;\">hem\u00f3lisis<\/span><span style=\"font-weight: 400;\">.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Existen otras estrategias que pueden ayudar a reducir los riesgos de la IgIV. Por ejemplo, los pacientes con trombosis pueden usar terapia antitromb\u00f3tica, o los pacientes con funci\u00f3n renal gravemente da\u00f1ada pueden recibir terapia de reemplazo renal a corto plazo antes del tratamiento con IgIV.\u00a0<\/span><br \/>\n&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Although intravenous immunoglobulin (IVIG) therapy is considered an effective and safe medical intervention for the treatment of various immune-mediated disorders, it also comes with its associated risks. These risks can be mild and transient, consisting of flu-like symptoms, or they can cause serious health problems such as stroke, or severe allergic reactions.\u00a0<\/p>","protected":false},"author":27,"featured_media":23824,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[33],"class_list":["post-23822","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-samantha-kaeberlein"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Understanding the Potential Risks of IVIG Therapy<\/title>\n<meta name=\"description\" content=\"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Understanding the Potential Risks of IVIG Therapy\" \/>\n<meta property=\"og:description\" content=\"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-23T20:38:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-04T22:48:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Samantha Kaeberlein, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Samantha Kaeberlein, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/\"},\"author\":{\"name\":\"Dr. Samantha Kaeberlein, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/aa941bb470287e10309b2fe7f5b15430\"},\"headline\":\"Understanding the Potential Risks of IVIG Therapy\",\"datePublished\":\"2024-01-23T20:38:27+00:00\",\"dateModified\":\"2025-06-04T22:48:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/\"},\"wordCount\":1255,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ivig-patient-1.jpg\",\"keywords\":[\"Dr. Samantha Kaeberlein\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/\",\"name\":\"Understanding the Potential Risks of IVIG Therapy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ivig-patient-1.jpg\",\"datePublished\":\"2024-01-23T20:38:27+00:00\",\"dateModified\":\"2025-06-04T22:48:03+00:00\",\"description\":\"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ivig-patient-1.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/ivig-patient-1.jpg\",\"width\":1280,\"height\":853,\"caption\":\"IVIG patient on bed receiving infusion.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/understanding-the-potential-risks-of-ivig-therapy-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Understanding the Potential Risks of IVIG Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/aa941bb470287e10309b2fe7f5b15430\",\"name\":\"Dr. Samantha Kaeberlein, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"caption\":\"Dr. Samantha Kaeberlein, PharmD\"},\"description\":\"Dr. Samantha Kaeberlein, PharmD was born and raised in Canton, OH. She received her pharmacy degree from Northeast Ohio Medical University (NEOMED) in 2020. The most rewarding part of her job is providing medical guidance so patients can make informed, well-rounded decisions regarding their healthcare. Her areas of expertise are geriatrics and long-term care. In her free time, she enjoys spending time outdoors, reading, and hunting for the best cup of coffee in America.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/samantha\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comprender los riesgos potenciales de la terapia con IgIV","description":"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/","og_locale":"es_MX","og_type":"article","og_title":"Understanding the Potential Risks of IVIG Therapy","og_description":"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-01-23T20:38:27+00:00","article_modified_time":"2025-06-04T22:48:03+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg","type":"image\/jpeg"}],"author":"Dr. Samantha Kaeberlein, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Samantha Kaeberlein, PharmD","Est. reading time":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/"},"author":{"name":"Dr. Samantha Kaeberlein, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/aa941bb470287e10309b2fe7f5b15430"},"headline":"Understanding the Potential Risks of IVIG Therapy","datePublished":"2024-01-23T20:38:27+00:00","dateModified":"2025-06-04T22:48:03+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/"},"wordCount":1255,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg","keywords":["Dr. Samantha Kaeberlein"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/","name":"Comprender los riesgos potenciales de la terapia con IgIV","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg","datePublished":"2024-01-23T20:38:27+00:00","dateModified":"2025-06-04T22:48:03+00:00","description":"This article discusses the various risks of IVIG, which can include things like allergic reactions, thrombotic events, infections, and more.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg","width":1280,"height":853,"caption":"IVIG patient on bed receiving infusion."},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-potential-risks-of-ivig-therapy-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"Understanding the Potential Risks of IVIG Therapy"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/aa941bb470287e10309b2fe7f5b15430","name":"Dra. Samantha Kaeberlein, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","caption":"Dr. Samantha Kaeberlein, PharmD"},"description":"La Dra. Samantha Kaeberlein, PharmD, naci\u00f3 y creci\u00f3 en Canton, Ohio. Obtuvo su t\u00edtulo en farmacia en la Universidad M\u00e9dica del Noreste de Ohio (NEOMED) en 2020. Lo m\u00e1s gratificante de su trabajo es brindar orientaci\u00f3n m\u00e9dica para que los pacientes puedan tomar decisiones informadas y completas sobre su atenci\u00f3n m\u00e9dica. Sus \u00e1reas de especializaci\u00f3n son la geriatr\u00eda y los cuidados a largo plazo. En su tiempo libre, disfruta de pasar tiempo al aire libre, leer y encontrar el mejor caf\u00e9 de Estados Unidos.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Samantha Kaeberlein, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"},"uagb_comment_info":0,"uagb_excerpt":"Although intravenous immunoglobulin (IVIG) therapy is considered an effective and safe medical intervention for the treatment of various immune-mediated disorders, it also comes with its associated risks. These risks can be mild and transient, consisting of flu-like symptoms, or they can cause serious health problems such as stroke, or severe allergic reactions.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/01\/ivig-patient-1.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Samantha Kaeberlein, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Although intravenous immunoglobulin (IVIG) therapy is considered an effective and safe medical intervention for the treatment of various immune-mediated disorders, it also comes with its associated risks. These risks can be mild and transient, consisting of flu-like symptoms, or they can cause serious health problems such as stroke, or severe allergic reactions.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/23822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=23822"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/23822\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/23824"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=23822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=23822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=23822"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}